The Use of Hydrogen Ion Water (Shan Shang Water) in the Treatment of Allergic Rhinitis
Launched by SECOND AFFILIATED HOSPITAL, SCHOOL OF MEDICINE, ZHEJIANG UNIVERSITY · Dec 25, 2024
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is exploring whether a special type of water called Shan Shang Water, which contains hydrogen ions, can help adults with allergic rhinitis, a condition that causes symptoms like sneezing, a runny or stuffy nose, and itchy eyes. The researchers want to find out if drinking this water can reduce these allergy symptoms and if it affects certain markers in the immune system. To do this, some participants will drink Shan Shang Water while others will drink a placebo, which is just a sugar water that doesn't have any active ingredients, for 24 weeks.
Participants in the trial should be between 18 and 65 years old and experience moderate to severe allergic rhinitis symptoms that significantly affect their daily lives. They will need to keep a diary of their symptoms and visit the clinic every four weeks for check-ups and tests. It's important to note that certain individuals, such as pregnant women and those with specific health conditions like liver or heart disease, won’t be able to participate. This trial is not yet recruiting participants, but it represents an exciting opportunity to explore a new potential treatment for a common allergy condition.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Intermittent or persistent recurrent bouts of sneezing, watery nose, itchy and stuffy nose may be accompanied by eye symptoms including itchy, watery eyes, red and burning eyes, with or without wheezing, coughing, shortness of breath and chest tightness shape.
- • The symptoms are more severe or severe, and have a significant impact on quality of life.
- Exclusion Criteria:
- • Pregnant women and parturients.
- • Patients with liver, kidney and heart disease.
- • Patients with past or current tumors.
- • Specific immunotherapy, biologics, or small molecule drug therapy is planned or initiated.
About Second Affiliated Hospital, School Of Medicine, Zhejiang University
The Second Affiliated Hospital of Zhejiang University School of Medicine is a leading clinical research institution dedicated to advancing healthcare through innovative medical practices and rigorous scientific inquiry. With a robust infrastructure and a multidisciplinary team of experienced researchers and clinicians, the hospital is committed to conducting high-quality clinical trials that address critical health challenges. As an integral part of Zhejiang University, the hospital leverages academic expertise and cutting-edge technology to foster collaboration in research, education, and patient care, ultimately aiming to improve patient outcomes and contribute to the global medical community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hangzhou, Zhejiang, China
Patients applied
Trial Officials
Huiying Wang
Study Director
2nd Affiliated Hospital, School of Medicine, Zhejiang University, China
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported